Live
FierceBiotechTrump slaps 100% duties on imported drugs but leaves plenty of exceptionsFierceBiotechBiopharma R&D pipeline shrinks for 1st time in 30 years: reportFierceBiotechADCs, TCEs among ‘exciting things’ on Boehringer’s dealmaking shopping listFierceBiotechMonths after $100M series A, Syneron closes $150M round to support peptide platformBioPharma DiveTrump revives pharma tariffs with 100% charges, but leaves loopholesPharmaVoiceAI’s next trick? Revealing new disease targets for drug R&DFierceBiotechChutes & Ladders—Bayer radiology head takes top U.S. pharma spotEndpoints NewsOpenLoop Health has acquired nutrition startup Season HealthFierceBiotechPremier Radiology acquires teleradiology specialist GLOBISFierceBiotech‘Portfolio assessment’ prompts Ferring to terminate 2 fertility trialsFierceBiotechUK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investmentsEndpoints NewsTrump signs order to put 100% pharma tariffs on drugs, countries without trade deals
PharmaVoice Apr 3, 2026

AI’s next trick? Revealing new disease targets for drug R&D

AI’s next trick? Revealing new disease targets for drug R&D

Original
Body unavailable. Use the original source.

Directory

59 All